SoftGenetics Joins Dotmatics, Expanding the Platform into Clinical and Forensic Genetics
Dotmatics has acquired SoftGenetics, a bioinformatics software company with over 22 years of expertise in advanced genetic analysis tools used in research, clinical, and forensic applications, thereby expanding Dotmatics' platform to enhance scientific discovery and improve clinical outcomes while maintaining SoftGenetics as a standalone business.
The continued acquisition of specialized software tools will accelerate scientific discovery and improve clinical outcomes.
BOSTON — June 12, 2023 — Dotmatics, a leader in R&D scientific software connecting science, data, and decision-making, announced it has acquired SoftGenetics, a bioinformatics software company that offers a range of advanced genetic analysis products for research, forensics, and healthcare applications.
“With more than 22 years of experience, SoftGenetics has deep expertise in a wide range of sequencing technologies, taking complex genetic data and making it actionable for clinicians and forensic investigators,” said Thomas Swalla, CEO of Dotmatics. “Adding these powerful genetic analysis tools strengthens the Dotmatics portfolio with more comprehensive and diverse solutions to help us advance scientific research, discovery, and clinical outcomes for our customers.”
SoftGenetics' products, known for their high sensitivity, accuracy, and low false positive rates, play a crucial role in research, healthcare, and forensics. The SoftGenetics product lineup includes 11 software solutions, with seven tailored for research and four designed for forensics. Among its most known products are Mutation Surveyor, enabling DNA variant analysis from Sanger Sequencing traces; NextGene, facilitating DNA variant analysis from NGS sequencing files; and GeneMarker, enabling genotyping analysis.
As it joins Dotmatics, SoftGenetics will remain a standalone business. Customers, partners, and distributors of SoftGenetics can expect continuing support from Dotmatics to amplify the impact, growth, and mission of SoftGenetics' business, which aligns with Dotmatics' mission to accelerate scientific discoveries and create a healthier, cleaner, safer world.
"This move presents an exciting opportunity for our SoftGenetics team to further expand the reach and impact of our genetic analysis products,” said Dr. Changsheng Liu, co-founder and vice president of R&D at SoftGenetics. “Joining the Dotmatics family will help us grow and scale at a much faster rate and with added financial and development resources, which is a win-win for our business and our customers.”
SoftGenetics is the 12th acquisition Dotmatics has made beginning with its initial acquisition of GraphPad in 2017, and the company intends to continue to grow both through internal product development and additional acquisition of specialized tools and services.
“This acquisition highlights Dotmatics' ongoing commitment to advancing scientific research by bringing together the best software tools across scientific disciplines,” said Jerome Combes-Knoke, senior vice president of corporate development at Dotmatics.
About Dotmatics
Dotmatics is a leader in R&D scientific software connecting science, data, and decision-making. Its enterprise R&D platform and scientists’ favorite applications drive efficiency and accelerate innovation. More than 2 million scientists and 10,000 customers trust Dotmatics to help them create a healthier, cleaner, safer world. Dotmatics is a global team of more than 800 people dedicated to supporting its customers in over 180 countries. The company’s principal office is in Boston, with additional offices and R&D teams located around the world.
Dotmatics is backed by Insight Partners, a leading global venture capital and private equity firm investing in high-growth technology and software scaleup companies. Learn more about Dotmatics, its platform, and applications including GraphPad Prism, Geneious, SnapGene, Protein Metrics, and LabArchives at https://www.dotmatics.com/.
Media Contact:
Cory Edwards
Vice President
Corporate Communications
Dotmatics
(801) 386-1960
cory.edwards@dotmatics.com
Related
What to know about antibody sequence analysis software
Antibody sequence analysis software, such as the Dotmatics platform powered by Geneious, facilitates the validation, characterization, selection, visualization, and export of antibody sequences—enabling scientists to efficiently analyze data from sources like Next-Generation Sequencing to support rational design and development of therapeutic antibodies.
Dotmatics Appoints Mike McKee as President and CEO
Dotmatics Ltd has appointed experienced technology CEO Mike McKee as its new President to accelerate the company's growth, scale its global team, double R&D investments, and lead integration efforts within Insightful Science's portfolio, succeeding founder Stephen Gallagher who will focus on strategic growth initiatives.
Dotmatics Acquires M-Star to Expand Presence in Bioprocessing and Chemicals & Materials Markets
Dotmatics has acquired M-Star, a computational fluid dynamics software company known for its GPU-accelerated, rapid simulation technology, to enhance its multimodal life sciences R&D platform and expand into bioprocessing, chemicals, and materials markets, enabling faster, more efficient fluid dynamics modeling critical for cell and gene therapy manufacturing.
What's New in Dotmatics Platform Version 6.1
Dotmatics Platform version 6.1 introduces a redesigned Inventory Module with enhanced hierarchies and workflows, modernized ELN form building with self-signing features, improved data discovery including multi-step reaction querying and large dataset exports, richer workspace visualizations, and expanded integrations supporting FAIR data principles and bidirectional biological sequence exchanges with tools like Geneious Prime, SnapGene, and Geneious Biologics.
Dotmatics Supports Umicore Corporate R&D in Processing of Experimental Data
Dotmatics has been chosen by Umicore Corporate R&D to implement its R&D innovation platform, including an electronic laboratory notebook for over 200 users, to digitalize and standardize data processing across Umicore’s Catalysis, Energy & Surface Technologies, and Recycling divisions, thereby enabling researchers to efficiently generate data-driven insights and accelerate innovation in materials science, chemistry, and metallurgy over the next five years.
Dotmatics Partners with Databricks to Advance Scientific Intelligence in Life Sciences
Dotmatics has partnered with Databricks to enhance scientific intelligence in life sciences by integrating Dotmatics’ Luma™ Scientific Intelligence Platform—supported by products like GraphPad Prism and Geneious—with Databricks’ data intelligence capabilities, enabling life science researchers to unify, analyze, and share large volumes of complex scientific data across various therapeutic discovery modalities such as antibody engineering, CAR-T, and CRISPR, thereby accelerating drug discovery and fostering a new paradigm in biopharmaceutical R&D.